Corinne Maurice‐Dror

1.1k total citations · 1 hit paper
35 papers, 576 citations indexed

About

Corinne Maurice‐Dror is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Corinne Maurice‐Dror has authored 35 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Corinne Maurice‐Dror's work include Cancer Immunotherapy and Biomarkers (15 papers), Cancer Genomics and Diagnostics (8 papers) and Prostate Cancer Treatment and Research (7 papers). Corinne Maurice‐Dror is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Cancer Genomics and Diagnostics (8 papers) and Prostate Cancer Treatment and Research (7 papers). Corinne Maurice‐Dror collaborates with scholars based in Israel, United States and Canada. Corinne Maurice‐Dror's co-authors include Hyun Cheol Chung, Antonio Jimeno, Todd M. Bauer, Ulka N. Vaishampayan, Jiaxin Niu, D.H. Lee, Drew Rasco, Jane Healy, Kathryn F. Mileham and Elliot Chartash and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Corinne Maurice‐Dror

33 papers receiving 571 citations

Hit Papers

First-in-human phase 1 st... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Corinne Maurice‐Dror Israel 12 425 220 148 102 100 35 576
Brigida Anna Maiorano Italy 15 343 0.8× 145 0.7× 125 0.8× 125 1.2× 88 0.9× 58 531
Gerry Gin Wai Kwok China 7 343 0.8× 131 0.6× 109 0.7× 79 0.8× 60 0.6× 10 518
Yun Hua Lee Singapore 5 291 0.7× 212 1.0× 109 0.7× 97 1.0× 78 0.8× 5 571
Shamayel Mohammed Saudi Arabia 7 599 1.4× 365 1.7× 113 0.8× 91 0.9× 50 0.5× 18 740
Filippos Kontos United States 8 252 0.6× 153 0.7× 75 0.5× 92 0.9× 87 0.9× 15 429
Marco Mora Italy 10 226 0.5× 276 1.3× 153 1.0× 95 0.9× 133 1.3× 19 571
Fumitaka Arihara Japan 7 327 0.8× 319 1.4× 95 0.6× 50 0.5× 78 0.8× 13 555
Annegé Vledder Netherlands 4 404 1.0× 307 1.4× 126 0.9× 139 1.4× 51 0.5× 9 626
Xinxin Shu United States 8 582 1.4× 196 0.9× 227 1.5× 98 1.0× 115 1.1× 11 686
Casilda Llácer Spain 7 334 0.8× 163 0.7× 77 0.5× 103 1.0× 48 0.5× 11 477

Countries citing papers authored by Corinne Maurice‐Dror

Since Specialization
Citations

This map shows the geographic impact of Corinne Maurice‐Dror's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corinne Maurice‐Dror with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corinne Maurice‐Dror more than expected).

Fields of papers citing papers by Corinne Maurice‐Dror

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corinne Maurice‐Dror. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corinne Maurice‐Dror. The network helps show where Corinne Maurice‐Dror may publish in the future.

Co-authorship network of co-authors of Corinne Maurice‐Dror

This figure shows the co-authorship network connecting the top 25 collaborators of Corinne Maurice‐Dror. A scholar is included among the top collaborators of Corinne Maurice‐Dror based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corinne Maurice‐Dror. Corinne Maurice‐Dror is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fadlullah, Muhammad Zaki Hidayatullah, David A. Nix, Cameron Herberts, et al.. (2025). Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectrum. 9(2).
2.
Nip, Ka Mun, Arman Rahmim, Robert H. Bell, et al.. (2025). Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer. JCO Clinical Cancer Informatics. 9(9). e2500105–e2500105. 1 indexed citations
3.
Bacon, Jack V. W., Cameron Herberts, Cecily Q. Bernales, et al.. (2025). Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma. npj Precision Oncology. 9(1). 177–177. 1 indexed citations
4.
Maurice‐Dror, Corinne, et al.. (2024). Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer. Future Oncology. 21(2). 201–211. 1 indexed citations
5.
Perets, Ruth, et al.. (2024). Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab.. Journal of Clinical Oncology. 42(16_suppl). 8631–8631. 6 indexed citations
6.
Soleimani, Maryam, Sajjad Janfaza, Sylwia Mazurek, et al.. (2024). Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma. Scientific Reports. 14(1). 8603–8603. 5 indexed citations
7.
Ritch, Elie, Cameron Herberts, Evan W. Warner, et al.. (2023). A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. npj Precision Oncology. 7(1). 27–27. 6 indexed citations
8.
Niu, Jiaxin, Corinne Maurice‐Dror, D.H. Lee, et al.. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Annals of Oncology. 33(2). 169–180. 196 indexed citations breakdown →
9.
Melero, Ignacio, Ravit Geva, Eytan Ben‐Ami, et al.. (2021). MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors. Annals of Oncology. 32. S313–S313. 4 indexed citations
10.
Maurice‐Dror, Corinne, et al.. (2021). Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(15_suppl). 5049–5049. 2 indexed citations
11.
12.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251. 6 indexed citations
13.
Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations
14.
15.
16.
Niu, Jiaxin, Adnan Nagrial, Mark Voskoboynik, et al.. (2020). 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Annals of Oncology. 31. S891–S892. 19 indexed citations
17.
Maurice‐Dror, Corinne, et al.. (2020). Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. Journal of Thrombosis and Thrombolysis. 50(1). 112–122. 3 indexed citations
18.
Cho, Byoung Chul, Kiyotaka Yoh, Jair Bar, et al.. (2019). Results From a Phase I Study of MK-1308 (ANTI–CTLA-4) Plus Pembrolizumab in Previously Treated Advanced Small Cell Lung Cancer. Annals of Oncology. 30. xi36–xi37. 3 indexed citations
19.
Moore, Assaf, Yael Bar, Corinne Maurice‐Dror, et al.. (2019). Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience. Head & Neck. 42(4). 599–607. 9 indexed citations
20.
Maurice‐Dror, Corinne, Ruth Perets, & Gil Bar‐Sela. (2018). Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander. Critical Reviews in Oncology/Hematology. 126. 37–44. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brigida Anna Maiorano Breakdown of academic impact, for papers by Gerry Gin Wai Kwok Breakdown of academic impact, for papers by Yun Hua Lee Breakdown of academic impact, for papers by Shamayel Mohammed Breakdown of academic impact, for papers by Filippos Kontos Breakdown of academic impact, for papers by Marco Mora Breakdown of academic impact, for papers by Fumitaka Arihara Breakdown of academic impact, for papers by Annegé Vledder Breakdown of academic impact, for papers by Xinxin Shu Breakdown of academic impact, for papers by Casilda Llácer
Rankless by CCL
2026